Evidence map›Paper›PMID 39551242›Full record

ArticleNeuropharmacology2025

The synthetic cannabinoid agonist WIN 55,212-2 reduces experimental pruritus via CB

Antonio Matt Reck, David P Siderovski, Steven G Kinsey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Antonio Matt ReckSchool of Nursing, University of Connecticut, Storrs, CT, USA; Department of Psychological Sciences, University of Connecticut, Storrs, CT, USA.
David P SiderovskiDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX, USA.
Steven G KinseySchool of Nursing, University of Connecticut, Storrs, CT, USA. Electronic address: steven.kinsey@uconn.edu.

Funding

Minor Cannabinoids and Terpenes: Preclinical Evaluation as AnalgesicsR01AT010773 · NCCIH · UPSTATE MEDICAL UNIVERSITY · PI GAMAGE, THOMAS F · 2019 to 2024
$2.5M
The role of RGS12 in differential modulation of G protein versus beta-arrestin signaling downstream of the kappa opioid receptorR01DA048153 · NIDA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI SIDEROVSKI, DAVID P. · 2021 to 2025
$1.8M
Stemming the opioid-induced pain cascade via cannabinoid modulationR21DA052690 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KINSEY, STEVEN G. · 2021 to 2022
$443k
NCCIH NIH HHS R01 AT010773NIDA NIH HHS R01 DA048153NIDA NIH HHS R21 DA052690
6 · The paper itself

Abstract

Pruritus (i.e., the experience that evokes a desire to scratch) is an adaptive process that can become maladaptive, leading to a persistent scratch-itch cycle that potentiates pruritus and increases the risk of infection. Cannabinoid drugs have been reported to decrease pruritus, but often at doses that also decrease locomotor activity, which confounds assessments of utility. To determine the utility of cannabinoids in treating pruritus without undesirable adverse effects, the current preclinical study investigated a range of doses of the synthetic cannabinoid agonist, WIN 55,212-2, and two minor Cannabis phytoconstituents, Δ

Indexed as

BenzoxazinesCannabinoid Receptor AgonistsDronabinolMice, Inbred C57BLMorpholinesNaphthalenesPolycyclic SesquiterpenesPruritusReceptor, Cannabinoid, CB2AnimalsAntipruriticsDose-Response Relationship, DrugFemaleIndolesMaleMice(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneAntipruriticsBenzoxazinesCannabinoid Receptor AgonistscaryophylleneDronabinolIndolesMorpholinesNaphthalenesPolycyclic SesquiterpenesReceptor, Cannabinoid, CB2SesquiterpenesAntipruritic agentCannabinoid receptorEndocannabinoid systemPruritusWIN 55,212-2β-caryophylleneΔ(8)-tetrahydrocannabinol

Identifiers

PMID39551242
PMCPMC11922163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.